Introduction
Cancer relapse and mortality are problems, despite conventional chemo-and biotherapies. The modest efficacy of treatments for human cancers suggests that therapies do not eradicate all malignant cells.
Decades ago, studies in mice introduced the idea of cancerinitiating cells, stating that distinct subpopulations of cells within the larger tumor mass are capable of driving tumorigenesis. 1 The isolation, characterization and functional analysis of cancer-initiating cells has been facilitated as of late by advances in tissue culture, cell sorting, animal transgenic and mouse-xenografting techniques.
The cancer-initiating cell theory was founded on the premise that tumor formation, growth and metastasis are governed by a distinct sub-population of cancer cells. In essence, the theory states that tumorigenesis and organogenesis are similar in many respects. After all, normal stem cells enable organ generation in the earliest stages of development and allow regeneration of tissues throughout the life span of an individual. In addition to maintaining their de-differentiated state by means of self-renewal, stem cells also give rise to progenitors that upon successive divisions differentiate to form cells of multiple lineages. Indeed, stem cells are among the longest lived cells present in the organism and are therefore more likely to accumulate the necessary mutations to render them tumorigenic.
Certain biochemical features of normal stem cells and cancer cells are similar. Loss of the tumor suppressor p53 by mutation, as evident in approximately 50% of human cancers, compromises the ability to balance cell death with increased proliferation. 2, 3 Normal hematopoietic progenitors repress p53-mediated apoptosis as well, even upon exposure to genotoxic insults. 4, 5 In addition, normal stem cells express the enzyme telomerase, which maintains the ends of chromosomes during successive rounds of DNA replication. 6 Telomerase activity serves to enhance life span by protecting chromosomal integrity at the telomeres. Over 90% of human cancers express telomerase suggesting that this is another way cells are selected for survival. 7 Although normal stem cells and cancer-initiating cells share certain features (that is, self-renewal and multilineage differentiation), cancer-initiating cells differ in their dysregulated proliferation and ability to invade and spread ( Figure 1 ).
Leukemia-initiating cells
Evidence for leukemia-initiating cells was first reported in 1994 when John Dick's laboratory isolated a rare population of CD34 þ CD38 À cells from patients with acute myeloid leukemia (AML). 8 Infusion of CD34 þ CD38 À cells into severe combined immune-deficient (SCID) mice resulted in leukemic blast generation; however, more differentiated cells (CD34 þ CD38 þ ) did not generate leukemia. Notably, secondary transplants, demonstrating self-renewal, were not possible in the SCID mouse, which still retains innate immunity. Thus, John Dick's group then used the NOD/scid mouse, deficient in both adaptive and innate immunity, to test the initiating capacity of CD34 þ CD38 À AML cells. In the NOD/scid mouse, leukemia induction was possible with lower numbers of CD34 þ CD38 À AML cells. In addition, the NOD/scid marrow niche permitted secondary AML cell xenotransplantation, demonstrating the feature of self-renewal. 9 In the end, it was proposed that myeloid leukemias were essentially hematopoiesis gone awry at the most primitive level and thus leukemia-initiating cells were malignant derivatives of normal hematopoietic stem cells (HSCs) (Figure 1 10 In acute lymphoblastic leukemia (ALL), conflicting reports have made our agreement over an ALL-initiating cell less concordant. In the 1980s and 1990s, several case reports described leukemia patients with successive leukemias (lymphoid then myeloid, or vice versa) containing the Philadelphia chromosome (Ph þ ) abnormality (BCR-ABL translocation). These successive leukemias of different lineages with the same DNA abnormality led physicians to believe that a primitive and malignant cell was at the root of Ph þ ALL. Subsequently, NOD/ scid mice were employed to test the leukemia-initiating capacity of human Ph þ ALL. Using the same experimental technique established in John Dick's laboratory, a French group determined that human Ph þ ALL arises from a primitive cell within the CD34 þ CD38 À fraction. 11 However, follow-up studies by other investigators have found that the Ph þ ALL-initiating story is more complex. Specifically, ALL with different Ph þ fusion products (p190 BCR-ABL vs p210 BCR-ABL) arise from different cell populations. The p210 BCR-ABL ALL are enriched for in the multipotent HSC population; whereas the p190 BCR-ABL ALL are enriched for in the lymphoid progenitor population. 12 Interestingly, despite in vitro evidence of primitive origin for p210 BCR-ABL ALL, in vivo xenotransplantation did not reconstitute in NOD/scid mice, suggesting that normal HSCs survive, albeit at low numbers. Whether this observation can be exploited for therapeutic purposes is to be determined.
In ALLs harboring different cytogenetic abnormalities, conflicting observations have been found. For example, in marrow samples from TEL/AML1-positive ALL patients, the CD34 þ CD19 À fraction contained little-to-no TEL-AML1 by reverse transcription (RT)-PCR. 13 The sample size was small in this study and the authors argue that sorter errors accounted for the little TEL-AML1 in the primitive CD34 þ CD19 À subset. In the end, the authors concluded that they could not enrich for the ALL-initiating cell using CD34 þ CD19 À sorting. Follow-up studies employing NOD/scid xenotransplant experiments confirmed this finding in TEL-AML1 ALL, finding that this leukemia likely arises in a lymphoid progenitor rather than a malignant multipotent hematopoietic cell. 15 Of note, the study included a heterogenous mixture of ALL patients with various cytogenetic abnormalities. The nature of the ALL-initiating cell remains to be defined and will likely be dependent upon the cytogenetic abnormality in question.
In chronic myeloid leukemia (CML) the malignancy is stem cell derived, but driven in myeloid progenitors. 16 CML is a proliferative disease in the bone marrow, originating in a multipotent HSC with an acquired translocation of chromosomes 9 and 22. This mutational event leads to the generation of a novel fusion gene, BCR-ABL. The gene product of this translocation is a constitutively expressed tyrosine kinase that deregulates signal transduction pathways leading to abnormalities in cell cycling, decreased apoptosis and increased cell proliferation. CML is clinically manifested in the granulocytic lineage, despite the fact that it originates in the HSC and its pathogenetic chromosome translocation can be found in all blood elements except T lymphocytes. With the advent of imatinib mesylate, interferon therapy has been supplanted as the standard of care. Imatinib directly targets the BCR-ABL-encoded tyrosine kinase activity in CML leading to decreased proliferation of myeloid progenitors. However, despite cytogenetic responses, molecular eradication of the disease is difficult and the current standard of care is to keep patients on imatinib indefinitely or until disease relapse or progression. The persistence of molecular disease is generally ascribed to evasion or resistance by quiescent CML-initiating cells. 17 Several strategies are now being developed to target resistant CML and it will be interesting to see how effective these new drugs effect apoptosis in CML-initiating cells.
Based on discoveries in Sean Morrison's laboratory, the signaling lymphocyte activation molecular (SLAM) family of immune cell receptors (CD150, CD244, CD48) are differentially expressed among normal hematopoietic stem and progenitor cells. 18 Specifically, HSCs have been found to express a CD150 þ CD244 À CD48 À phenotype and has been abbreviated as the HSC SLAM code. Ongoing investigations in hematologic malignancies seek to determine if this same SLAM code also identifies leukemia-initiating cells.
Translating discoveries of leukemia-initiating cells will hopefully uncover opportunities to exploit aberrant leukemia pathways. It was recently reported that the tumor suppressor phosphatase and tensin homolog (PTEN) is directly linked to leukemia-initiating cell activation and subsequent myeloproliferative disease and leukemia. 19, 20 PTEN is a cytoplasmic phosphatase that negatively regulates signaling via the phosphoinositide 3-kinase (PI3K)/AKT pathway and serves to keep proliferation under control, allowing HSCs to maintain a state of suspended quiescence. Conditional deletion of PTEN in HSCs initially resulted in rapid HSC proliferation and the subsequent progression of myeloproliferative disease. However, only leukemia-initiating cells harboring the deletion were selected for survival and therefore capable of reconstituting the disease in mice. A causative relationship between PTEN and leukemogenesis was confirmed by rescue of the disease with administration of the mTOR inhibitor rapamycin, which suppresses downstream effectors of PI3K signaling. Thus, as PTEN loss is a characteristic of leukemia-initiating cells in acute leukemia, its associated signaling networks may be of therapeutic interest.
The isolation and characterization of leukemia-initiating cells has also prompted interest in studying the molecular pathways promoting their survival, with the intent of eliminating this population, while sparing normal stem cells. Hope for achieving this aim arose from the discovery that nuclear factor-kB is activated in AML, most likely as a survival mechanism in response to anthracycline chemotherapy. 21 A clever strategy was devised to exploit this phenomenon and attempt to target leukemia-initiating cells that acquire drug resistance. Combination treatment with an anthracycline agent, idarubucin, and proteosome inhibitor, MG-132, was found to specifically sensitize leukemia-initiating cells to apoptosis in a murine model. 22 Capitalizing on another aberrant pathway in leukemia, intense research is being conducted to determine whether FMS-like tyrosine kinase 3 (FLT3) mutations in AML are in the leukemia-initiating cell or a subclone progeny. AML and B-cell leukemias often overexpress FLT3 RNA and protein, 23 and approximately one-third of AML patients have a mutation in FLT3. 24 This mutation is usually an internal tandem duplication (ITD), but can also be a point mutation involving the kinase domain (KD). The resultant effects of FLT3 mutations are downstream activation of proliferation and inhibition of apoptosis and differentiation through the PI3K/AKT, JAK/STAT and Ras/MAPK pathways. In patients, following the allelic ratio of mutant FLT3 to wild-type FLT3 has prognostic importance, with higher ratios indicating poorer prognosis with conventional chemotherapy. 25 To determine where the FLT3 mutation resides in AML cellular hierarchy, investigators have used the NOD/scid mouse xenotransplantation model. 26 Results in these translational studies indicate FLT3 mutant CD34 þ CD38 þ leukemiainitiating cells retain allelic ratio after injection, implying that this population of AML cells are enriched for the leukemiainitiating cells which contain the FLT3 mutation. Furthermore, a small molecule FLT3 inhibitor hampered AML engraftment. Several FLT3 inhibitor trials are currently underway. However, the experience analyzing patient samples has indicated a different situation. In patients with a history of FLT3 ITD mutation AML, the mutation is present at relapse in most patients; but, in some (approximately 20% of cases) it is not, suggesting that the FLT3 ITD mutation occurred in a subclone and not the leukemia-initiating cell. 27 In patients with history of FLT3 KD mutation AML, more than half of relapses do not contain the mutation, further suggesting that this particular mutation may reside in a subclone. 28 Besides their role in maintaining hematopoiesis, primitive cells derived from the bone marrow also possess the ability to differentiate into endothelial cells of the vasculature. Endothelial progenitor cells and HSCs are believed to originate from a common hemangioblastic precursor during embryonic development. 29 We have also shown that the adult HSC is capable of providing hemangioblast activity. 30, 31 In addition, evidence suggests that leukemia cells exhibit hemangioblast activity as well, because endothelial cells harboring the BCR-ABL gene fusion have been detected in patients with CML. 32 In B-cell lymphoma patients, lymphoma-specific genetic alterations were similarly found in endothelial cells comprising the microvasculature. 33 Studies are currently underway to determine if leukemia-initiating cells contribute to blood vessels in terms of vasculogenesis or vascular mimicry. If leukemia-initiating cells are a true source of endothelial cells, then blood vessels may be a sanctuary site for later leukemia relapse. If so, future therapies for leukemia may include adjuvant anti-angiogenic therapy.
The leukemia-initiating cell niche has also been an active area of investigation. Efforts to find differences in the environmental needs of leukemia-initiating cells compared to normal HSCs/hematopoietic progenitor cells (HPCs) could point to more effective ways to prevent leukemia-initiating cell homing, migration and proliferation. Specifically, the endosteal niche, known to support HSC/HPC self-renewal, 34, 35 also expresses ligands, which assist HSCs/HPCs to gain entry into the marrow microenvironment. In addition, leukemia-initiating cells rely on a supportive marrow microenvironment. Recently, CD44 was implicated as a crucial leukemia-initiating cell surface protein, permitting tethering to marrow stroma and subsequent leukemia development. Mechanistic studies blocking CD44/stroma binding inhibited leukemia-initiating cell migration to the spleen and marrow, and drove the leukemia-initiating cells to differentiate into more mature states. 36, 37 Differences in blocking techniques, leukemias tested and mouse models have also been accompanied by differences in leukemia inhibition. Whether these differences in results are due to experimental techniques, CD44 isoforms or levels of CD44 expression on leukemia-initiating cell still need to be determined in order for CD44 targeting to move closer to the clinic.
Also in the niche, the stromal-derived factor-1 (SDF-1)/CXCR4 and vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR-1) axes have shown importance. [38] [39] [40] Interestingly, CXCR4 and VEGFR-1 are also expressed on normal hematopoietic stem and progenitor cells. Future research may seek to identify the degree of CXCR4 expression on putative cancer-initiating cells. Moreover, the idea that VEGFR-1 þ HPCs prepare the metastatic 'soil' for immigrating cancer-initiating cells highlights opportunities to interfere with tumor invasion and spread. Already, small molecule inhibitors of the SDF-1/CXCR4 axis inhibits metastases in preclinical experiments and anti-VEGF antibody therapy has shown clinical responses. 38, 41 The discovery of cancer-initiating cells in leukemia was the impetus to work toward the prospective identification of tumorinitiating cells in other cancers. If leukemia and other hematologic malignancies do indeed result from the aberrant regulation of the normal hematopoietic program, then a similar concept of cancer evolution could be applied to nonhematologic malignancies.
Cancer-initiating cells in solid tumors

Brain
The isolation and characterization of cancer-initiating cells in solid tumors was facilitated by the development of a novel in vitro method for the selection of self-renewing cells within human gliomas. 42 The neurosphere system developed by the Steindler laboratory entailed obtaining clinical biopsies of cerebral cortex glioma tissues from patients with brain cancer and culturing single cell suspensions of the gliomas in a serumdeprived media on an attachable substratum. Self-renewing neurosphere-forming cells comprised approximately 0.1% of biopsied glioma cells (Figure 2 ). Subsequent transfer of the spherical clones to an adhesive substrate and supplementation with serum yielded positive immunostaining for neuronal and astroglial proteins. RT-PCR confirmed the expression of nestin, a marker for self-renewal, which occurred concurrently with elevated neuronal-and astroglial-specific mRNAs The concomitant induction of genes specific to self-renewal and neural lineage commitment was preliminary evidence that brain tumors may be organized as a cellular hierarchy, in which outgrowth was governed by a small population of stem-like cells. A similar observation was reported when normal tissue was grown in the neurosphere system, thus suggesting fundamental similarities between normal neurogenesis and gliomagenesis.
Two years after this discovery, the Dirks laboratory addressed the functional characteristics of these putative cancer-initiating cells by sorting the CD133 þ and CD133 À populations and transplanting them into the frontal lobes of immunodeficient mice. Disease recapitulation was evident when as few as 100 CD133 þ cells were infused; however, this engraftment efficiency was severely limited or absent altogether upon transplantation of unsorted or CD133 À cells. 43 In addition, the CD133 þ grafts demonstrated high levels of positive immunostaining for the neuronal precursor proteins vimentin and nestin, while total tumor heterogeneity was confirmed by the expression of lineage specific proteins including glial fibrillary acidic protein (GFAP) and b-III tubulin. Self-renewal capacity of the CD133 þ cells was confirmed by serial transplantation of the tumors in mice and noting similarities in phenotypic heterogeneity between the newly arisen tumor and primary human tumor. Thus, CD133
þ cells residing within gliomas are selfrenewing and give rise to a tumor hierarchy reminiscent of that found in leukemia. Similar results were subsequently reported by Galli et al. 44 For patients with glioblastomas, radiation therapy has been the cornerstone of treatment. However, disease remissions are transient and glioma relapses are common. Given the earlier findings that gliomas are a heterogenous mixture of cells and that CD133 þ glioma cells enrich for the glioma stem cell, Bao et al. 45 questioned whether the radioresistance of brain cancer is due to an invulnerable glioma stem cell. In both cell culture and xenografts, CD133
þ glioma-initiating cells survived ionizing radiation as compared to the rest of the bulk tumor. The glioma-initiating cells repaired radiation-induced DNA damage better than the bulk tumor. These results suggest that radiation therapy fails because it cannot kill the CD133 subpopulation of glioma-initiating cells. Furthermore, by inhibiting checkpoint kinases, Chk1 and Chk2, the radio-responsive kill of CD133 glioma-initiating cells can be heightened, illuminating new strategies to enhance radiotherapy. As this radio-sensitizing technology is taken to the clinic, avoiding unwanted necrosis of surrounding normal brain tissue may be a challenge.
Targeting the relatively undifferentiated state of gliomainitiating cells, Piccirillo et al. 46 recently reported studies demonstrating that bone morphogenetic proteins, which normally mature neural precursor cells, also mature CD133 þ glioma-initiating cells. By forcing this differentiation, brain tumor-forming capacity of glioma stem cells was critically weakened. These results illuminate a new strategy of differentiation therapy for treatment of gliomas. In the future, differentiation agents may be applied to gliomas to make them more amenable to surgical, radiotherapy, and/or chemotherapy eradication. This strategy is akin to retinoic acid treatment for patients suffering with acute promyelocytic leukemia.
Breast
In 2003, Al-Hajj et al. reported evidence of cancer-initiating cells within human breast tumors. 47 Tumorigenic cells sorted from metastatic breast carcinomas were established phenotypically as CD44 þ CD24 À/low Lineage À , with expression of epithelial surface antigen (ESA) further enriching for breast cancerinitiating cells. Tumor recapitulation occurred when as little as 100 of these cells were infused into NOD/scid mice; however, 10 5 or greater of the CD44 þ CD24 þ counterparts, or unsorted cells from the primary tumor did not contribute to de novo tumorigenesis.
To elucidate the signaling pathways relevant to breast cancerinitiating cell function, the investigators utilized a similar in vitro clonogenic sphere system as described previously for the selection of glioma-initiating cells. 42 Mammospheres grown under anchorage independent and serum withdrawal conditions were compelled to differentiate upon attachment to a collagen substratum, and expression of genes implicated in stem cell selfrenewal was compared between the different culture conditions. Hedgehog (Hh) signaling was found to be prevalent in the stem/progenitor population while downregulated upon differentiation-a transition likely mediated by the polycomb gene Bmi-1, 48 which had previously been implicated in leukemia-initiating cell self-renewal. 49 In assessing breast cancer-initiating cell function, it was found that the previously characterized CD44 þ CD24 À/low Lineage À population exhibited an increase in Hh signaling compared to their CD44 þ CD24 þ counterparts, suggesting that a mechanism of self-renewal driven by Hh signaling promotes mammary tumorigenesis. Dedifferentiation, or the acquisition of self-renewal capacity from a cell previously undergoing symmetrical division may be a crucial hit in cancer-initiating cell function. 
SPOTLIGHT
found evidence of a small subpopulation of self-renewing cells which expressed genes normally restricted to embryonic stem cells and primordial germ cells (Figure 3) . 51 Pluripotency genes Oct3/4 and Nanog were expressed during 'sarcosphere' formation, but expression dropped upon attachment and differentiation. Having preliminarily identified the putative sarcomainitiating cells as mesenchymally derived Stro-1 þ CD44 þ CD105 þ cells, further in vivo investigations will strengthen the case for tumorigenicity.
Evidence from Chinese investigators has found that mesenchymal bone marrow cells may be a source of cancers. 52 Tissue culture plate adherent mouse marrow cells were grown in culture and then exposed to a potent carcinogen, 3-methycholanthrene (MCA). After a week of MCA exposure, the cells were injected into immunodeficient mice. Within 2 months, tumors grew and displayed histology consistent with leiomyomas, hemangioedhothelioma, fibrosarcoma, sarcomatoid carcinoma, neurilemoma and other poorly differentiated tumors. These studies indicate that marrow cells which are adherent to fibronectin-coated tissue cultures have the capacity to be transformed into malignancies of all three germ layers. Recently, there has been evidence of a very small embryonic-like (VSEL) cell in adult bone marrow with capability of producing all three germ layers. 53 VSELs, which interestingly also express CXCR4 and respond to an SDF-1 gradient, may be a candidate marrowderived cancer-initiating cell. Further studies are warranted.
Gastrointestinal
Research by Vogelstein et al. 54 over the past three decades has defined the sequential genetic mutations that command the evolution of human colorectal oncogenesis. Despite this molecular discovery, new strategies are needed to combat relapsed disease after surgical resection.
Employing a similar strategy utilized in the prospective identification of cancer-initiating cells in brain and breast tumors, two laboratories recently reported enriching for human colon cancer-initiating cells using antibodies to the primitive cell surface protein CD133. 55, 56 When human colon cancer biopsies were sorted for CD133 þ cells and then subsequently xenografted in immunodeficient mice, cancer sphere formation and tumor recapitulation resulted with a similar phenotypic hierarchy noted in the primary tumor. Tumor-initiating frequency was estimated at one in 3000 CD133
þ colon cancer cells in the model employing subcutaneous-Matrigel assay; 55 whereas, tumor initiation frequency was slightly lower employ- (Fluorescein (FITC) ), and the cells that express the astroglial marker glial fibrillary acidic protein (GFAP) are stained blue (7-amino-4-methylcoumarin-3-acetic acid (AMCA)). The arrowhead in (f) points out a cell that is not labeled for GFAP, but is immunopositive for b-III tubulin (arrowhead in g). The short arrow in (f) points out a cell that is immunolabeled for GFAP, but immunonegative for b-III tubulin (short arrow in g). The long arrows in f and g point to a cell that is labeled with both immunomarkers. Scale bars are 10 (f and g) and 100 mm (a-e). This figure is from Ignatova et al., GLIA, 2002, and is reprinted with permission from Wiley Press.
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ing kidney capsule implantation. 56 Such engraftment efficiencies are reminiscent of the relatively scant number of CD44 þ CD24 À/low Lineage À breast and CD133 þ brain cancerinitiating cells needed to recapitulate their respective tumors in a similar mouse model. 43, 47 CD133 is found in normal adult intestinal tissue, and future studies will be needed to affirm these early findings.
Taking a different track, Houghton et al. recently questioned the role of bone marrow as a source of gastric cancer. The premise was built upon the correlation of Helicobacter pylori and risk of developing gastric cancer. In recent years, a more sophisticated understanding of the molecular virulence mechanisms of this bacterial pathogen has strengthened the case for a causal relationship between H. pylori infection and gastric tumorigenesis. 57, 58 Since H. pylori causes a chronic inflammatory state within the gastric mucosa and because of the relationship between inflammation and oncogenesis, Houghton et al. hypothesized that marrow responding to chronic inflammation also contributed to the neoplastic gastric glands. 59 To test this hypothesis, bone marrow harvested from a male donor was infused into female C57BL/6 mice chronically infected with H. pylori. After hematopoietic engraftment, gastric adenomas were harvested and found to contain neoplastic glands containing male/ marrow-derived epithelial cells. Based on these results the authors purport that marrow can be a primary source of cancer.
As a possible alternate explanation to Houghton's findings, we recently observed that marrow contributes to human and murine neoplasias as developmental mimicry rather than as seeds of cancer. Using a unique study schema, we studied colonic adenomas from women who received hematopoietic cell transplantations from male siblings. Adenomas detected 1 to 3 months after transplantation demonstrated low levels of marrow-derived adenoma epithelial cells (male, cytokeratin positive, CD45-negative cells) incorporated within the adenomas (Figure 4 ). Confocal microscopy demonstrated no evidence of fusion karyotype (that is, XXY or XXXY). Furthermore, the marrow-derived cells were found in the basal strata of the adenomas and at low frequency, suggesting that marrow was not contributing as a primary source, but more likely as a developmental mimic. To confirm these findings, we employed the APC min mutant mouse model of intestinal neoplasia. After performing gender-mismatched hematopoietic cell transplant, intestinal adenomas harvested from recipient mice demonstrated the exact same findings as in our human patients: marrow-derived cells incorporated in the adenomas, expressed cytokeratin, lost hematopoietic cell surface proteins, lacked evidence for fusion and occurred at very low levels (less than 1% of all adenoma cells). Collectively, these studies offer an alternate explanation of the interaction of marrow and solid neoplasias, demonstrating developmental mimicry ( Figure 5 ).
In the setting of developmental mimicry, marrow cells are called into epithelial environments following inflammatory cues. Recently, the SDF-1/CXCR-4 axis has been recognized as crucial to hematopoietic progenitor recruitment in environments of ischemia and tumor initiation. 60, 61 Then through the influence of growth factors and cell-cell contacts, the marrow cells undergo cell fate changes, mimicking the surrounding Based on the observations in identifying breast cancerinitiating cells, it was recently found that pancreas cancer also contains an initiating cell population with a similar phenotype. Using the NOD/scid mouse xenotransplant schema, Li et al. found 100-fold tumorigenicity with CD44 þ CD24 þ ESA þ pancreatic cancer cells. 62 Furthermore, these pancreatic cancerinitiating cells demonstrated self-renewal and expressed the stem cell signaling molecule, sonic Hh. Identification of this pancreatic cancer-initiating cell population will hopefully lead to better mechanistic insights in this notoriously chemotherapyand radiation-resistant cancer.
Lung
The high prevalence of chemotherapeutic resistance in lung cancer has stimulated interest in finding the initiating cell origin of this heterogeneous disease. Although conventional chemotherapy regimens lessen the bulk of lung tumor and temporarily keep the disease at bay, a lingering subpopulation of drug-resistant cancer-initiating cells may regenerate the tumor and eventually metastasize. Moreb et al. 63 have attributed the chemoresistance of non-small cell lung cancer (NSCLC) to elevated expression of ALDH, which is a cytosolic enzyme involved in the oxidization of intracellular aldehydes and metabolism of retinoid compounds. Previously, ALDH was identified as a functional marker of HSCs and believed to serve in detoxifying harmful substances that would otherwise insult these crucial cells. 64 Flow cytometric analyses strategies that employ both surface marker expression and ALDH activity have been used both to enrich for HSCs and in discerning primitive and progenitor cell populations isolated from umbilical cord blood. 65 Recent evidence suggests that ALDH expression may also be a functional marker of a leukemia-initiating cell. 66 Utilizing a mouse model of NSCLC in which disease is initiated by activation of the K-ras oncogene, preliminary data from Tyler Jack's laboratory points to bronchioalveolar stem cells (BASCs) as candidates for chemo-resistant lung cancerinitiating cells (ISSCR Annual Meeting Abstracts, 2006). However, much further testing is needed to properly identify the role of BASCs in lung cancer.
Prostate
Stem cells residing in the basal region of the prostate epithelium self-renew and differentiate to form secretory cells of the prostate gland. There is evidence that these cells or their immediate progeny, the transit amplifying cells, are the origin of prostate intraepithelial neoplasias (PIN) 67 and that loss of p27 kip1 , a cyclin-dependent kinase inhibitor, is the principal mediator of PIN initiation. 68 Using a mouse model, the surface protein stem cell antigen-1 (Sca-1) was found to enrich for prostate stem cells that could initiate tumorigenesis upon disruption of normal PTEN tumor suppressor function. 69, 70 Also shown in a mouse model for leukemia and myeloproliferative disease, 19, 20 conditional deletion of PTEN from prostate stem cells resulted in a drastic increase in Sca-1 þ cells concurrently expressing high levels of the antiapoptotic Bcl-2 protein, spurring postulation that these cells are likely prostate cancer-initiating cells. 71 Such findings will enable investigators to undertake future experiments and determine if appropriately purified Sca-1 þ Bcl-2 þ cells can recapitulate prostate cancer in immunodeficient mice. The role for PTEN in cancer-initiating cell function in leukemia and androgen-independent prostate cancer warrants further investigation into how this tumor suppressor may be implicated in the stem cell origin of other cancers.
Work by Maitland and Collins previously identified prostate stem cells from normal prostatic epithelial tissues based on expressions of integrin a2b1 and CD133. 72, 73 These investigators have subsequently determined that the a2b1
þ subpopulation of pancreatic cancer also identifies a cancer-initiating cell population. 62 Follow-up in vivo studies will strengthen these early observations.
Conclusions
Cancer-initiating cells in hematologic and solid tissue malignancies share key characteristics of normal stem cells such as self-renewal, multilineage differentiation, quiescent maintenance and drug resistance. Assays used in normal stem cell biology (for example, LTC-IC, NOD/scid xenograft) have been adapted to cancer cells and have successfully identified several cancer-initiating cell populations. The identification of additional isolation methods for cancer-initiating cells in other solid tumors will follow; however, the definitive existence of cancerinitiating cells will most likely be proven in much the same way as were normal stem cells. Indeed, lineage-tracing studies will be required to address the role of cancer-initiating cells as the roots of cancer. Already, leukemia studies have led the way in this regard. Additionally, the question of whether a cancer-initiating cell initiates cancer or whether a dysregulated cancer cell acquires stem-like capabilities has yet to be answered definitively.
Furthermore, several factors may influence cancer cell selfrenewal, differentiation, and invasiveness including (i) the degree of the specific cell's dysregulated genome, (ii) the niche within which the cell resides and (iii) time. These variables may make it possible for several cancer cells to be identified as cancer-initiating cells.
Nevertheless, the existence of cancer cells with stemlike capabilities has inaugurated the next generation of targeted cancer therapies. A chief translational goal is to identify mechanistic differences between normal stem cells and cancerinitiating cells. Exploitation of these differences could ultimately lead to complete cancer eradication.
